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A distinct mechanism for ubiquitin (Ub) ligation has
recently been proposed for the RING1-IBR-RING2
(RBR) family of E3s: an N-terminal RING1 domain
recruits a thioester-linked intermediate complex
between Ub and the E2 UbcH7, and a structurally
distinct C-terminal RING2 domain displays a cata-
lytic cysteine required for Ub ligation. To obtain
insights into RBR E3s, we determined the crystal
structure of the human homolog of Ariadne (HHARI),
which reveals the individual RING1, IBR, and RING2
domains embedded in superdomains involving
sequences specific to the Ariadne RBR subfamily.
The central IBR is flanked on one side by RING1,
which is exposed and binds UbcH7. On the other
side, a C-terminal autoinhibitory ‘‘Ariadne domain’’
masks the RING2 active site. Insights into RBR E3
mechanisms are provided by structure-based muta-
tions that indicate distinct steps of relief from autoin-
hibition, Ub transfer from E2 to HHARI, and ligation
from the HHARI cysteine to a terminal acceptor.
INTRODUCTION
Ubiquitin (Ub) is ligated to targets through the coordinated action
of E1 (ubiquitin activating), E2 (ubiquitin conjugating), and E3
(ubiquitin ligase) enzymes. First, the activated Ub protein is typi-
cally transferred between E1 and E2 active site cysteines. Sec-
ond, the resultant covalent thioester-linked E2Ub intermediate
uses an E3 enzyme. E3s utilize a variety of mechanisms to cata-
lyze Ub ligation to targets. Many E3s function as activating scaf-
folds that directly transfer the C terminus of Ub from the E2 active
site to a substrate Lys. This category is exemplified by the large
family of RING E3s (Deshaies and Joazeiro, 2009). RING
domains typically coordinate two zinc ions in a cross-braced1030 Structure 21, 1030–1041, June 4, 2013 ª2013 Elsevier Ltd All ristructure via Cys, His, and occasionally other side chains.
Notably, structural studies have revealed how RING domains
bind both E2 and Ub to optimally orient and activate the
E2Ub intermediate for nucleophilic attack, and how RING
E3s can bind both a substrate and E2Ub to position a sub-
strate’s acceptor Lys adjacent to an associated E2 active site
(Calabrese et al., 2011; Dou et al., 2012a; Plechanovova´ et al.,
2012; Pruneda et al., 2012).
Another mechanism by which E3s can promote Ub ligation
involves Ub transfer from the E2 to a Cys on the E3 itself, gener-
ating a thioester-linked E3Ub intermediate. It is thought that
Ub is ultimately transferred from the E3 catalytic cysteine to
the target. The first thioester-forming E3s to be identified were
members of the HECT family (Huibregtse et al., 1995; Scheffner
et al., 1995), and a prior structural study revealed how the
HECT catalytic domain binds both E2 and Ub for Ub transfer
to the E3 Cys (Kamadurai et al., 2009). More recently, several
thioester-forming E3 ligases have been identified from patho-
genic bacteria, which are thought to hijack the host Ub system
during infection processes (Anderson and Frank, 2012). These
bacterial E3 ligases are structurally unrelated to HECT E3s,
but nevertheless bind E2 for Ub transfer to the E3 catalytic
Cys (Diao et al., 2008; Huang et al., 1999; Lin et al., 2012;
Quezada et al., 2009; Singer et al., 2008; Verdecia et al.,
2003; Zhu et al., 2008). Active forms of both HECT and bac-
terial thioester-forming E3s often undergo autoubiquitination,
reflecting the high degree of reactivity of the E3Ub thioester
intermediate.
Recently, a landmark study revealed a variant mechanism for
the RING1-IBR (in-between-RING)-RING2 (RBR) family of E3s
(Wenzel et al., 2011). RBR E3s have a RING1 domain for E2 bind-
ing that shares many features of standard RING E3s. However,
the finding that the RING1 domain of some RBRs binds the
E2 UbcH7 (Ardley et al., 2001; Moynihan et al., 1999), which
was reported to transfer Ub only to cysteines and not to lysines,
led to the reclassification of RBRs as ‘‘RING-HECT hybrids’’
(Wenzel et al., 2011). A conserved unliganded Cys in a second,
structurally distinct ‘‘RING2’’ domain is required for RBR
E3-mediated autoubiquitination or free Ub chain formationghts reserved
Figure 1. HHARI Is Inactive for Autoubiquitination, but, Unlike Parkin, Binds UbcH7
(A) SYPRO-Ruby-stained reducing SDS-PAGE gel after time course incubating full-length HHARI or Parkin with E1 (Uba1), UbcH7, Ub, and MgATP.
(B) Gel filtration chromatography profiles of Parkin or HHARI alone (green), UbcH7 (red), and of Parkin or HHARI mixed with UbcH7 (blue). SYPRO-Ruby-stained
SDS-PAGE gels of fractions from the gel filtration peaks are shown below chromatograms. For reference to relative migration during chromatography, the same
data with UbcH7 are shown below both chromatograms.
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Structure and Autoinhibition of the RBR E3 HHARIin vitro, which are readouts for Ub ligation activity (Wenzel and
Klevit, 2012; Wenzel et al., 2011). The corresponding Cys is
mutated in the RBR E3 Parkin in some cases of Parkinson dis-
ease and is also required for Parkin to bind its substrates and
for Parkin-mediated substrate ubiquitination in cells (Lazarou
et al., 2013; Nuytemans et al., 2010; Sarraf et al., 2013).
The best understood RBR E3s are the autosomal recessive
juvenile Parkinson disease-associated protein Parkin, the het-
erotrimeric linear ubiquitin chain assembly complex (LUBAC)
that contains both the HOIP and HOIL-1L RBR proteins, and
members of the Ariadne subfamily (Marı´n, 2009; Wenzel and
Klevit, 2012). Parkin and LUBAC have been implicated in regu-
lating mitochondrial dynamics and NF-kB signaling, respec-
tively (Ikeda et al., 2011; Kitada et al., 1998; Tokunaga and
Iwai, 2012; Tokunaga et al., 2011). The Ariadne subfamily is
the largest RBR cohort, with Ariadne-type RBR E3s found in
all eukaryotes including yeast. In addition to a central RBR
catalytic domain, Ariadne-family RBRs are characterized by a
C-terminal ‘‘Ariadne domain’’ (Marı´n and Ferru´s, 2002). Two
human E3s, ARIH1/HHARI and ARIH2/TRIAD1, are closely
related to Drosophila Ariadne. Other more divergent Ariadne
subfamily members have evolved to contain additional
domains, such as CUL9/PARC, which has an N-terminal
cullin-homology domain, and ANKIB1, which has N-terminal
ankyrin repeats (Marı´n and Ferru´s, 2002). Although specific
pathways regulated by Ariadne subfamily members are rela-
tively poorly understood, their functional importance has been
shown with genetic studies. For example, Drosophila Ariadne
is essential for development (Aguilera et al., 2000). Murine
Arih2 is also required for embryogenesis, and reconstitution
of hematopoetic lineages with Arih2 null fetal liver cells leads
to lethal activation of the immune response (Lin et al., 2013).Structure 21, 10The yeast Ariadne subfamily member Hel1 (‘‘histone E3
ligase 1’’) is important for degrading exogenously expressed
histone H3 (Singh et al., 2012).
Although truncated forms of the proteins are active, full-
length Parkin and HOIP proteins are inactive on their own
(Chaugule et al., 2011; Smit et al., 2012; Stieglitz et al., 2012).
These two E3s are thought to be autoinhibited through distinct
mechanisms because they lack obvious sequence homology
beyond their RBR domains. In the case of Parkin, an N-terminal
Ub-like domain binds between the IBR and RING2 domains to
lock the E3 in an inactive conformation (Chaugule et al.,
2011). In vivo, Parkin is activated through recruitment to the
mitochondrial membrane and phosphorylation by the PINK1
kinase (Kondapalli et al., 2012; Lazarou et al., 2012, 2013;
Sha et al., 2010). In contrast, HOIP is activated within the
LUBAC complex by interaction with either of its HOIL-1L and/
or SHARPIN partner proteins (Ikeda et al., 2011; Kirisako
et al., 2006; Smit et al., 2012; Stieglitz et al., 2012; Tokunaga
et al., 2011).
Given the emerging appreciation of RBRs as a distinct
family of E3 ligases, it is important to understand the structural
basis for their functions. Although there are structures of
isolated E2-binding canonical RING E3s, an RBR-specific
IBR, and RING2 domains, there is no structure of a full
RING1-IBR-RING2 E3 (Beasley et al., 2007; Capili et al.,
2004; Dou et al., 2012b; Plechanovova´ et al., 2012; Pruneda
et al., 2012; Zheng et al., 2000). To address this problem, we
determined the crystal structure of HHARI. Taken together
with biochemical experiments, the data provide structural
insights into RBR E3s and reveal how a thioester-forming E3
ligase is autoinhibited by a conserved domain masking its
active site cysteine.30–1041, June 4, 2013 ª2013 Elsevier Ltd All rights reserved 1031
Table 1. Crystallographic Data and Refinement Statistics
Data Collection Crystal Form 1 Crystal Form 2
Wavelength (l) 0.9798 0.9798
Space group P41 P63
Unit Cell Parameters
a, b, c (A˚) 147.6, 147.6,
87.34
96.1, 96.1, 151.3
a, b, g () 90, 90, 90 90, 90, 120
Resolution (A˚) 46.67–3.30 36.47–3.60
No. of measured
reflections
84,920 95,159
Original Truncateda
No. of unique reflections 27,938 9,276 8,348
Overall Rsym (%) 4.9 (84.3) 9.2 (49.2) 8.8 (15.0)
Completeness (%) 98.1 (96.4) 99.9 (99.9) 89.9 (17.6)
Overall I/sI 14.8 (1.3) 25.8 (3.0) 27.8 (15.9)
Mean redundancy 3.0 10.2 (9.4) 10.4 (11.1)
Refinement
Rwork/Rfree 0.231/0.283 0.270/0.299
Rmsd bond lengths (A˚) 0.008 0.011
Rmsd bond angles () 1.4 1.2
Subunits in asymmetric
unit
2 1
No. of Atoms
Protein 6,569 3,133
Zinc 12 6
Ramachandran Statistics
Residues in favored
regions (%)
95.8 94.1
Residues in disallowed
regions (%)
0.1 0.0
See also Figure S2.
aTruncated values correspond to statistics after elliptical truncation
prompted by severe anisotropy.
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Full-Length HHARI Binds the E2, UbcH7, but Is Inactive
with Generic Readouts for E3 Ligase Function
In vitro activities of Parkin and HOIP have been best character-
ized through either autoubiquitination, which is a common
read-out for E3 ligase activity, or free Ub chain formation (Chau-
gule et al., 2011; Smit et al., 2012; Stieglitz et al., 2012; Wenzel
et al., 2011). Whereas their RBR domains are active in these
assays, both Parkin and HOIP proteins are autoinhibited in their
full-length forms (reviewed in Dove and Klevit, 2012). Thus, we
wondered whether a common feature of RBR E3s is their main-
tenance in an inactive state. We examined intrinsic, substrate-
independent E3 ligase activity of the human homolog of Ariadne
(HHARI), which shares no apparent homology with Parkin and
HOIP beyond the RBR domain, and obtained a similar negative
result (Figure 1A).
A fundamental requirement for E3 ligase function is binding to
the E2. We therefore examined binding of full-length Parkin and
HHARI to their reported cognate E2, UbcH7, by comigration1032 Structure 21, 1030–1041, June 4, 2013 ª2013 Elsevier Ltd All riover gel filtration chromatography. Unlike Parkin, HHARI and
UbcH7 copurify by this method (Figure 1B). Taken together,
the results raised the possibility that HHARI is maintained in
an architecture that allows E2 binding but prevents E3 ligase
activity.
Overall Structure of HHARI: An Elongated Architecture
Assembled from Multiple Domains
To gain insights into HHARI architecture, we crystallized the full-
length HHARI protein and determined the structure from crystals
growing in the space group P41 to a resolution of 3.3 A˚ (Table 1;
Figures S1 and S2 available online). Initial phases were obtained
with MAD based on the six tightly bound zinc atoms in the native
protein. Anomalous data on crystals of selenomethionine-
labeled HHARI, as well as data collected from eight individual
site-specific mutants, incorporating one additional selenome-
thionine residue at a time, guided creation of the structure (Fig-
ure S1). Because the P41 crystal form contained two molecules
per asymmetric unit, we also determined the structure from a
second crystal form in the space group P63, with a single mole-
cule of HHARI per asymmetric unit. Despite great effort at opti-
mization, anisotropy of data collected from the P63 form limited
the resolution and refinement. Nonetheless, the high quality
electron density confirmed the overall features of the structure
in the P63 form and suggested that HHARI is a monomer (Figures
S1 and S2). Indeed, the molecular weights of HHARI measured
by sedimentation velocity analytical ultracentrifugation of
66.9 kDa and by size exclusion chromatography-multiangle light
scattering of 62.2 kDa agree well with the calculated molecular
weight of 64.2 kDa for a monomer (Figure S2). Thus, in general,
we describe a single molecule of HHARI from the P41 crystal
form.
HHARI adopts an extended, roughly 90 A˚ long assembly of
multiple domains: a b strand, a three-helix bundle that unex-
pectedly adopts a UBA domain-like fold, RING1, a two-helix
RING1-to-IBR linker, the IBR, RING2, and the Ariadne domain.
Several of these domains pack with each other to form superdo-
mains (Figure 2). The HHARI N-terminal 98 residues were
required for expression and crystallization, although this region,
which contains 30 glycines and 36 acidic residues, was not
visible in the electron density from either crystal form. Residues
154–184 linking the UBA-like domain and RING1, and 328–338
linking the IBR and RING2 were likewise not visible and are not
modeled.
At the center of the HHARI structure is the IBR, which superim-
poses on the prior nuclear magnetic resonance (NMR) structure
of the IBR domain from HOIP with 3.2 A˚ root-mean-square devi-
ation (rmsd; Figure 2C). Embeddedwithin the IBR structure is the
most N-terminal region visible in the structure (residues 99–105),
which we term ‘‘IBR-interacting strand’’ due to its forming part of
a three-stranded b sheet with two strands from the IBR. On one
side of the IBR, a discontinuous helical domain containing the
UBA-like domain and the RING1-to-IBR linker connect the IBR
and RING1. RING1 superimposes well onto structures of canon-
ical RING domains, such as that from c-Cbl with 2.4 A˚ rmsd
(Figure 2C).
C terminal of the IBR, RING2 adopts a different zinc-binding
fold. Of the eight cysteines in RING2, seven are involved in coor-
dinating two zinc atoms (Figure S3). One zinc is coordinatedghts reserved
Figure 2. Structure of HHARI
(A) Schematic view of domain structure of HHARI. Colored boxes correspond to the IBR-interacting strand (IIS), UBA-like, RING1, RING1-to-IBR linker, IBR,
RING2, and Ariadne domains observed in the crystal structure. White boxes correspond to regions not visible in the electron density. The location of the catalytic
Cys357 is indicated in orange.
(B) Two views, rotated 90 around the x axis, of one molecule in the asymmetric unit for HHARI determined from the P41 crystal form, with the IBR-interacting
strand in maroon; the UBA-like domain in violet; the RING1, IBR, and RING2 domains in slate; the RING1-to-IBR linker in tan; and the Ariadne domain in green.
Zinc atoms are shown as yellow spheres.
(C) Individual domains from the RBR superimposed on related structures: HHARI RING1 (slate) superimposed on a canonical RING domain as shown from c-Cbl
(Protein Data Bank [PDB] ID: 1FBV, pink); HHARI IBR domain (slate) superimposed on the IBR domain from HOIP (PDB ID: 2CT7, pink); and HHARI RING2
manually docked via its C-terminal zinc-binding site on the NMR structure of the isolated HHARI RING2 bound to only a single zinc atom (PDB ID: 1WD2, pink).
See also Figure S1.
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Structure and Autoinhibition of the RBR E3 HHARIby four cysteines from two two-stranded antiparallel b sheets.
The C-terminal cysteine in the terminal b strand connects to a
loop-like structure in which two other cysteines and a histidine
face inward to coordinate a second zinc atom. This latter zinc-
binding site can be manually docked partially onto the corre-
sponding region from a prior NMR structure (Figure 2C) (Capili
et al., 2004). The RING2 domain also contains a single unli-
ganded cysteine, Cys357, in agreement with the prior finding
suggesting this as the only unliganded cysteine in RING2:
treatment of a purified RING2 domain with the thiol reactive
4-(2-iodoacetamido)-TEMPO results in a single modification,
only to Cys357 (Wenzel et al., 2011). Cys357 is the conserved
RBR catalytic cysteine shown previously to be required for
autoubiquitination of a GST-fusion of the RBR domain from
HHARI (Wenzel et al., 2011).
TheC-terminal Ariadne domain adopts an elongated four-helix
bundle consisting of an antiparallel arrangement of seven-to-
ten-turn long helices. The Ariadne domain is straddled on one
side by the IBR domain, and on the other by the RING2 domain.
Notably, the Ariadne domain embraces the surface of RING2
containing the catalytic Cys357 (Figure 2B).Structure 21, 10Ariadne Domain Masks the HHARI Catalytic Cys357 and
Inhibits Intrinsic E3 Activity
An extensive, highly conserved surface from RING2 packs in a
broad 25 A˚ by 35 A˚ cleft formed by three of the four helices in
the Ariadnedomain (Figures 3A, 3B, andS3). This interaction bur-
ies a total of 1,000 A˚2 from both proteins, including more than
30% of the total surface from RING2 and 122 contacts between
the domains (Table S1). This intramolecular interaction is secured
by extensive contacts from a surface including Asn423, Ser427,
Phe430, Glu431, and Glu503 from the Ariadne domain cradling
the RING2 loop spanning from Lys353 to Asn358, which includes
thecatalyticCys357 (Figure3C). Thecontacts extend to theC ter-
minus of RING2, anchored by Arg420 from the Ariadne domain
making a hydrogen bond to the carbonyl from the most C-termi-
nal zinc ligand (Cys389) from RING2, and Phe416 from the
Ariadne domainmaking van der Waals contacts to the backbone
extending from Cys389 to the terminus of the RING2 domain.
The structure suggests that the lack of intrinsic E3 ligase activ-
ity may result from the Ariadne domain blocking RING2. We
performed several assays to test this idea. First, we found that
a deletion mutant of HHARI lacking the Ariadne domain30–1041, June 4, 2013 ª2013 Elsevier Ltd All rights reserved 1033
Figure 3. The Ariadne Domain Binds RING2
to Mediate Autoinhibition
(A) The Ariadne domain (green) masks the RING2
(slate) surface containing the catalytic Cys357
(sulfhydryl shown as orange sphere). Zinc atoms
are shown as yellow spheres.
(B) The IBR and RING2 domains are shown in
surface representation, colored by conservation
among Ariadne family members, with the Ariadne
domain shown in green cartoon.
(C) Close-up view of intramolecular contacts
between the Ariadne domain (green) and RING2
domain (slate, with catalytic Cys357 sulfhydryl
represented as a small orange sphere, and zinc
atoms as yellow spheres).
(D) SYPRO-Ruby-stained reducing SDS-PAGE
gels showing time courses of autoubiquitination of
the full-length or mutant form of HHARI with the
Ariadne domain deleted (HHARIDAri) in the pres-
ence of E1 (Uba1), E2 (UbcH7), Ub, and MgATP.
(E) SYPRO-Ruby-stained reducing SDS-PAGE
gels showing time courses of autoubiquitination of
HHARIDAri in the presence or absence of the iso-
lated Ariadne domain (HHARIAri) or a mutant
(HHARIAri (mut)) in the structurally observed RING2-
binding surface (F430A, E431A, and E503A).
(F) SYPRO-Ruby-stained reducing SDS-PAGE
gels showing time courses of autoubiquitination of
wild-type full-length HHARI or indicated mutants
with alanine substitutions in the RING2-binding
surface of the Ariadne domain.
See also Figure S3.
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Structure and Autoinhibition of the RBR E3 HHARI(HHARIDAri) is extensively autoubiquitinated (Figure 3D). Second,
the isolated Ariadne domain (HHARIAri) restores inhibition when
added in trans to HHARIDAri (Figure 3E). Importantly, the negative
control mutant harboring Ala substitutions in Phe430, Glu431,
and Glu503 (HHARIAri(mut)) from the structurally observed
RING2-binding surface fails to block E3 ligase activity, consis-
tent with the notion that the Ariadne domain binds to RING2 to
mediate inhibition (Figure 3E). Third, Ala mutations in the struc-
turally observed RING2-binding surface of the Ariadne domain
are sufficient to activate both autoubiquitination of and free Ub
chain formation by full-length HHARI (Figure 3F).
To determine whether the Ariadne domain blocks the initial Ub
transfer from UbcH7, we developed a pulse-chase assay. First,1034 Structure 21, 1030–1041, June 4, 2013 ª2013 Elsevier Ltd All rights reservedwe enzymatically generated a fluorescent
UbUbcH7 thioester intermediate and
quenched E1-mediated loading of
UbcH7 by adding apyrase to eliminate
ATP and prevent recharging. The
UbUbcH7 intermediate is stable in
the presence of a mutant version of
HHARIDAri with the catalytic Cys357
substituted with alanine (Figure 4A). How-
ever, the addition of wild-type HHARIDAri
results in loss of the thioester-linked
UbcH7Ub intermediate and concomi-
tant formation of nonreducible com-
plexes with the fluorescent Ub linked to
both HHARIDAri and UbcH7, both beingsources of available lysines in the reactions (Figures 4A and
4B). Notably, upon addition of the isolated Ariadne domain, but
not the version mutated in the RING2-binding surface, the
thioester-linked UbcH7Ub intermediate persists and Ub liga-
tion is inhibited (Figure 4A). The results are consistent with the
Ariadne domain blocking the catalytic cysteine from RING2 to
prevent formation of a HHARIUb intermediate.
The Canonical RING1 Packs against the RING1-to-IBR
Linker Helices for Recruitment but Not Activation of E2
Our identification of the Ariadne-RING2 domain interaction as
responsible for autoinhibition enabled interrogation of other
functional regions of HHARI through biochemical assays with
Figure 4. The Ariadne Domain Inhibits Ub
Transfer from UbcH7 to HHARI
(A) Fluorescence scans of nonreducing SDS-PAGE
gels showing timecourses of the ‘‘chase’’ inwhich the
thioester-linked fluorescent lysine-less UbK0UbcH7
intermediate was incubated with HHARIDAri in the
presence or absence of the isolated Ariadne domain
(HHARIAri) or the mutant (HHARIAri(mut)) in the struc-
turally observed RING2-binding surface (F430A,
E431A, and E503A).
(B) Same experiment as (A), but after samples were
reduced with DTT.
See also Table S1.
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Structure and Autoinhibition of the RBR E3 HHARIthe active HHARIDAri mutant. The HHARI structure provides a
framework for understanding previous mutagenesis data
defining requirements for interacting with the E2, UbcH7:
coimmunoprecipitation of HHARI and UbcH7 from mammalian
cells required both HHARI’s RING1 and residues 238–273 (Moy-
nihan et al., 1999; Ardley et al., 2001). Residues 238–273 form the
RING1-to-IBR linker, which packs tightly against RING1 to form
an integrated RING1/RING1-to-IBR1 structural unit (Figure 2).
The RING1-to-IBR1 linker also packs against the N-terminal
UBA-like domain. Although it is tempting to speculate a role for
the UBA-like domain, we see no effect of making aspartate sub-
stitutions in place of surface hydrophobic residues that might be
predicted to bind Ub’s hydrophobic Ile44 patch (Figure S4).
Thus, future studies will be required to ascertain functional roles
of the UBA-like domain fromHHARI. In a related vein, in previous
studies, deleting the Ariadne domain had no effect on the asso-
ciation of HHARI and UbcH7 in mammalian cells (Moynihan
et al., 1999). Accordingly, the Ariadne domain is structurally
distal and separated from RING1 and the RING1-to-IBR linker
and is dispensable for their copurification by gel filtration
in vitro (Figure 5A). Interestingly, the activated version of HHARI
lacking the autoinhibitory Ariadne domain binds slightly tighter to
UbcH7 (roughly 190 versus 540 nMKdmeasured with isothermal
titration calorimetry), although future studies will be required to
determine the basis for this enhanced affinity (Figure 5B).
Docking models of a HHARI-E2Ub complex, generated by
superimposing RING domains from HHARI and RNF4 or BIRC7
in complexes with E2Ub (Dou et al., 2012b; Plechanovova´
et al., 2012), show Ile188 at the center of the interaction with
E2 (Figures 5C and 5D). Previously, mutation of Ile188 or zinc-
binding ligands required for formation of the RING1 fold abol-
ished HHARI-UbcH7 complex formation (Ardley et al., 2001;
Wenzel et al., 2011). We find that an Ile188Ala mutation substan-
tially decreases intrinsic E3 ligase activity for the activated
HHARIDAri construct (Figure 5E).Structure 21, 1030–1041, June 4, 201RING2 Active Site Loop Residues
Contribute to Ub Ligation
Although HHARI’s Cys357 is required for
Ub ligation, we inferred that an intermediate
must be highly reactive because we
were unable to unambiguously trap a sub-
stantial fraction of HHARIDAri thioester-
linked to Ub. This agrees with previous
studies of truncated, active forms of Parkin,HOIP, and HHARI that either likewise failed to observe an inter-
mediate or reported only an extremely small proportion of total
E3 as forming a reducible thioester-linked E3Ub complex
(Smit et al., 2012; Stieglitz et al., 2012; Wenzel et al., 2011).
Thus, to gain insights into RBR-mediated catalysis, we examined
the structure around the HHARI active site (Figure 6A) to identify
residues potentially involved in ligation. If residues exist that spe-
cifically contribute to ligation, then in theory their mutation would
allow stabilization of the thioester-linked E3Ub intermediate.
Immediately C terminal of the catalytic Cys357 are two polar
residues, Asn358 and His359, conserved among Ariadne sub-
family members. Although Asn358 does not directly contact
Cys357 and the Cys357 sulfhydryl makes a hydrogen bond to
the backbone oxygen from His359, we considered that the
present structure represents an inactive conformation and
also lacks a covalently linked Ub. Thus, these side chains are
poised to potentially contribute to E3 ligase activity in an
activated but presently unknown conformation whereby HHARI
is thioester-bonded to Ub. In our pulse-chase assay, the
UbcH7Ub thioester intermediate decreased in the presence
of the activated HHARIDAri construct and for Asn358Ala and
His359Ala mutants. However, under the conditions of our assay,
the majority of the HHARIDAriUb product formed by the two
mutants was the DTT-reducible thioester intermediate (Fig-
ure 6B).We conclude that both Asn358 andHis359 are important
for the reaction mediating Ub ligation to a terminal acceptor,
at least in the context of the intrinsic reactivity reflected by
autoubiquitination.
DISCUSSION
The structure of HHARI represents one of few for a full-length E3
ligase and any RBR E3. Taken together with previous data, the
structure provides insights into how the RING1, IBR, and
RING2 domains common among RBR E3s are assembled,3 ª2013 Elsevier Ltd All rights reserved 1035
Figure 5. Recruitment of UbcH7 to HHARI RING1 Is Required for Intrinsic Autoubiquitination Activity
(A) Gel filtration chromatography profiles of HHARIDAriadne (HHARIDAri) alone (green), UbcH7 alone (red), or a mixture of HHARIDAri and UbcH7 (blue). SYPRO-
Ruby-stained SDS-PAGE gels of fractions from the gel filtration peaks are shown below chromatograms.
(B) Isothermal titration calorimetry data for interactions between UbcH7 and wild-type (WT) HHARI or HHARIDAri. Upper panels show raw power data recorded
during the titration experiments, and lower panels show fits of standard binding equations after integration of the raw data using Origin (v. 7.0) software provided
by MicroCal.
(C) Surface representation of HHARI with UbcH5aUbiquitin from the RNF4UbcH5aUbiquitin complex (PDB ID: 4AP4) modeled onto RING1. The positions of
the catalytic cysteines are marked by orange spheres. Ile188, a mutant defective in E2 binding, is shown in red.
(D) Close-up view of the predicted E2-RING1 interaction showing the positions of UbcH7 Phe62 and HHARI Ile188.
(E) SYPRO-Ruby-stained SDS-PAGE gel showing a time course for autoubiquitination of HHARIDAri or HHARIDAri Ile 188A.
See also Figure S4.
Structure
Structure and Autoinhibition of the RBR E3 HHARIreveals that HHARI and most likely other Ariadne subfamily
members share the property of being autoinhibited with Parkin
and HOIP, and offers molecular details into the basis of autoin-
hibition and the two-step Ub ligation mechanism. It is of great
interest to understand mechanisms for both activating
and attenuating RBR E3 activity for therapeutic purposes in
Parkinson disease and immune hyperactivation (Kitada et al.,
1998; Lin et al., 2013; Tokunaga and Iwai, 2012). Analysis of
the Parkin sequence in light of the HHARI structure reveals1036 Structure 21, 1030–1041, June 4, 2013 ª2013 Elsevier Ltd All riseveral Parkinson disease mutations poised to disrupt the IBR
structure, RING1 recruitment or positioning of E2Ub, or cata-
lytic activities of the RING2 domain (Figure S3).
Surprisingly, RING1, IBR, and RING2, which are the only
regions conserved among all RBR E3s, are widely separated
from each other but form integral interactions with sequences
that are found only in Ariadne subfamily members. For RING1,
this involves the region leading to the IBR domain that
likely structurally stabilizes the RING1 domain, explaining theghts reserved
Figure 6. RING2 Mutations that Stabilize
E3 Ubiquitin-Thioester Intermediate Reveal
Residues Required for Ligation Reaction
(A) Cartoon representation of RING2 (slate)
showing residues from the catalytic loop. RING2
zinc ions are shown as yellow spheres.
(B) Fluorescence scans of SDS-PAGE gels
showing time courses of the ‘‘chase’’ in which the
thioester-linked fluorescent UbUbcH7 interme-
diate was incubated with HHARIDAri or HHARIDAri
catalytic loopmutants N358A or H359A. Top panel
is nonreducing. Bottom panel is reducing.
Structure
Structure and Autoinhibition of the RBR E3 HHARIrequirement of RING1-to-IBR linker helices for binding to
HHARI’s partner E2 UbcH7 (Ardley et al., 2001). Despite display-
ing the overall fold of a RING E3, HHARI’s RING1 lacks
an arginine utilized by some RING domains to structurally inter-
calate between E2 and Ub to support ‘‘folding back’’ of Ub
against E2 and allosterically activate discharge of some thio-
ester-linked E2Ub intermediates (Dou et al., 2012b; Hamilton
et al., 2001; Plechanovova´ et al., 2012; Pruneda et al., 2012;
Reverter and Lima, 2005; Saha et al., 2011; Wickliffe et al.,
2011). This is consistent with our finding that the UbcH7Ub
is stable in the presence of the HHARIDAri catalytic Cys357Ala
mutant (Figure 4) and the previous finding that a construct en-
compassing the HHARI RING1 and IBR domains was inactiveFigure 7. Superposition of the Crystal Forms Shows Domain
Variation Hinging at the IBR
Superposition of the P63 crystal form (gray) with the P41 crystal form of HHARI
aligned over their IBR domains to show structural variability. Arrows indicate
directions of domain rotations between the P41 and P63 crystal forms. The
individual domains all superimpose well as shown.
Structure 21, 1030–1041, June 4, 2013 ªat stimulating UbcH5CUb discharge to
lysine (Wenzel et al., 2011). Thus, taken
together, the data suggest that theRING1/RING1-to-IBR module recruits UbcH7 much like other
RING domains bind to E2s, but like HECT E3s, may proceed
through catalysis with E2Ub in different conformation than
that utilized by canonical RING E3s (Kamadurai et al., 2009).
In the context of full-length HHARI, the catalytic RING2
domain differs from the previous NMR structure of the isolated
domain (Capili et al., 2004) but agrees with biochemical data
showing Cys357 as the sole unligandedCys in this domain (Wen-
zel et al., 2011). Our finding ofmutations that allow persistence of
an E3Ub thioester intermediate in a pulse-chase assay both
confirms the proposed RING-HECT hybrid mechanism for
RBRs (Wenzel et al., 2011) and suggests that there are distinct
requirements for the two steps of transferring Ub from E2 to an
RBR E3 and ligating Ub from the RBR active site cysteine to a
terminal lysine (Figure 6). It will be exciting in the future to learn
if these features reflect conformational malleability of RING2
for catalysis.
Our biochemical data allowHHARI to join the growing list of E3
ligases that are autoinhibited in their full-length forms, albeit
through a wide range of mechanisms that include blocking sub-
strate or E2-binding, masking the active site cysteine, and pre-
venting attainment of an active conformation (Dou et al.,
2012a; Dove and Klevit, 2012; Du et al., 2002; Dueber et al.,
2011; Gallagher et al., 2006; Kobashigawa et al., 2011; Lopez
et al., 2011; Wiesner et al., 2007; Yamoah et al., 2008). Although
the reasons why E3s may be autoinhibited remain largely
unknown, it seems likely that this could provide a mechanism
for preventing misdirected autoubiquitination, thereby steering
Ub ligation to substrates in the correct biologic context.
Interestingly, each family of RBR E3 seems to display unique
mechanisms of autoinhibition, with the Ariadne-family-specific
‘‘Ariadne domain’’ blocking HHARI activity in at least two
ways. First, the catalytic Cys357 is masked and thus inacces-
sible for forming an intermediate. Second, in the structure,
the Ariadne domain is intercalated between the IBR and
RING2, contributing to a wide separation between the pre-
dicted active site on a RING1-bound E2 and HHARI’s catalytic
Cys357 in RING2 (Figure 5). Thus, in addition to the requirement
for exposing the RING2 active site, HHARI apparently must
undergo substantial structural rearrangement for Ub transfer
from E2 to the catalytic cysteine. Indeed, our data do reveal
structural variability even in full-length HHARI. Although overall2013 Elsevier Ltd All rights reserved 1037
Figure 8. Models for RBR E3 Ligase Activa-
tion
(A) Two possible models for HHARI activation.
Posttranslational modification (PTM) of the
Ariadne domain could disrupt the interaction with
RING2 and allow for RING2Ub thioester forma-
tion and subsequent ubiquitination of substrate.
Another possible activation mechanism would
involve another protein binding to HHARI to
release the Ariadne domain from RING2.
(B) Current model for Parkin activation whereby
PINK1 phosphorylates the UblD domain and re-
leases its autoinhibitory effect.
(C) Current model for HOIP activation where HOIL-
1L and Sharpin UBL domains interact with HOIP to
release autoinhibitory domains and promote
ubiquitination of NEMO.
Structure
Structure and Autoinhibition of the RBR E3 HHARIfeatures of HHARI are shared in the P41 and P63 crystal forms,
superimposition of the two structures reveals hinges between
the IBR domain and the RING1/RING1-to-IBR linker on one
side, and the RING2 and Ariadne domain on the other (Figure 7).
These and other unknown but malleable regions of the structure
may enable the conformational changes required for catalysis
of E2-to-E3 Ub transfer and subsequent Ub ligation. We antic-
ipate many exciting future studies revealing structural mecha-
nisms of RBR E3 activities.
Although at this point the physiologic mechanisms relieving
autoinhibition and allowing UbcH7Ub to approach HHARI’s
active site are unknown, it seems likely future studies will reveal
activation mechanisms related to those stimulating Parkin or
HOIP, such as posttranslational modifications at HHARI’s
Ariadne-RING2 interface, or the Ariadne domain binding to other
partners to liberate RING2 (Figure 8). Interestingly, different
structure-based activating HHARI mutants displayed a range
of activities and substrate-independent ubiquitination patterns
in our assay. Future studies may reveal gradients of endogenous
mechanisms regulating autoinhibition to allow fine-tuning rather1038 Structure 21, 1030–1041, June 4, 2013 ª2013 Elsevier Ltd All rights reservedthan binary control of enzyme activity for
HHARI and other RBR E3s.
EXPERIMENTAL PROCEDURES
X-Ray Crystallography
Crystals of full-length HHARI were grown with the
hanging drop vapor diffusion method and
appeared in two distinct morphologies. Crystal
form 1 grew in 1.0–1.4 M potassium/sodium
tartrate/0.1 M CHES pH 9.5/0.2 M LiSO4 at room
temperature, in the space group P41 with a = b =
146.9, c = 86.62, and a = b = g = 90. Crystal
form 2 grew in 0.5–0.55 M tri-sodium citrate/
0.1 M citric acid pH 5.2/0.2 M lithium acetate at
room temperature, in the space group P63 with
a = b = 96.1, c = 151.3, a = b = 90, and g = 120.
The structure of crystal form 1was initially deter-
mined with zincMAD in P41212 with six sites found
using HKL2MAP (Sheldrick and Schneider, 1997).
In space group P41212, one molecule was found
in the asymmetric unit corresponding to a 74%
solvent content according to the Matthews coeffi-
cient (Matthews, 1968). Viewing the packing alongthe C axis showed large solvent channels 48 A˚ across, which account for the
high solvent content. The resolution of the phases went to 3.5 A˚, although the
quality of the maps appeared much lower because of missing electron density
for several sections of main chain residues and nearly all the side chains. The
structures of several domains solved previously were docked into the electron
density maps to guide manual model construction, but the R and Rfree failed to
drop below 0.45. To further guide structure construction, selenomethionine
(SeMet) scanningwasusedwhere eight individual leucine-to-methioninemuta-
tions were made. The versions of HHARI containing SeMet were then crystal-
lized (Huang et al., 2004). Se-SAD data sets were collected for each of these
eight mutations and confirmed the position by the appearance of new anoma-
lous difference density surrounding the site but failed to yield superior electron
density maps using space group P41212. Overall, the density was still of poor
quality and difficult to build. At this point, a systematic approach was followed
to determine what could be causing the refinement problem. The results indi-
cated the presence of noncrystallographic symmetry (NCS), namely, rotational
pseudosymmetry (RPS). RPS can occur when the point-group symmetry of the
lattice is higher than that of the crystal (Zwart et al., 2005). Similar cases of RPS
have been seen in other structures (Chacko et al., 2012; Lougheed et al., 2001;
Zagotta et al., 2003). In our case, the true spacegroup isP41with twomolecules
in the asymmetric unit. The NCS operator has a kappa value of 179.94, only
0.06 from being crystallographic in space group P41212 and the overall
rmsd between the C-alpha atoms is 0.6 A˚. The resulting electron density map
Structure
Structure and Autoinhibition of the RBR E3 HHARIin P41 is superior in quality showing continuous density and nearly all of the side
chains were visible, allowing for unambiguous sequence assignment, and the
refinement proceeded to acceptable R-factor and Rfree values (Table 1).
Because merohedral twinning is a possibility in P41, the structure was refined
in Phenix (Afonine et al., 2012), including the twin operator (h, -k, -l), but the
resulting R-factor and Rfree increased by 1% and 2%, respectively, and the
electrondensitymapsshowednovisible improvement compared to refinement
excluding the twin operator. Therefore, the structure was refinedwithout a twin
operator.
Initial electron density maps for crystal form 2 were obtained with MR-SAD
with a partial molecular replacement model taken from the model built for
crystal form 1 dissected into domains. Due to severe anisotropy of the data
(3.9 A˚ along a and b and 3.4 A˚ along c), the initial electron density maps
were relatively featureless and hindered building and refinement. Therefore,
the data were anisotropically scaled using the UCLA anisotropy server
(Strong et al., 2006). Following ellipsoid truncation using a reciprocal lattice
origin with vertices 1/3.9, 1/3.9, and 1/3.4 A˚ along a, b, and c, respectively,
the completeness of the highest resolution bin was only 2% (96% complete
prior to truncation). The data were rescaled to 3.6 A˚ and the 9,276 merged
reflections were elliptically truncated using 3.8 A˚ along a and b and 3.6 A˚
along c (resolution limits determined by the server), resulting in 8,348 reflec-
tions. A negative B factor correction of 79.20 A˚2 was applied along c. The
anisotropically scaled data were used in refinement with Phenix (Afonine
et al., 2012). The quality of the electron density was significantly improved
and refinement proceeded as expected. Model construction and refinement
for both crystal forms were done in Coot and Phenix (Afonine et al., 2012;
Emsley and Cowtan, 2004).
Enzyme and Binding Assays
Multiple turnover assays were done at room temperature with 150 nM Uba1,
500 nM UbcH7, 20 mMUbiquitin, and 250 nM HHARI. All reaction components
were mixed in 25 mM Tris pH 7.6, 2.5 mM MgCl2, 2.5 mM ATP, and 20 mM
NaCl, and reactions were initiated with the addition of Uba1. Reactions were
quenched at the indicated time points in SDS-PAGE sample buffer containing
50 mM DTT except where indicated as nonreducing, resolved on 4%–12%
gradient gels (Invitrogen), and visualizedwith SYPRO-Ruby stain. For inhibition
assays, HHARIDAri and HHARIAri were mixed on ice for 10 min prior to reaction
initiation.
Pulse-chase assays were done on ice. For fluorescent labeling, a cysteine
residue was introduced into lysineless ubiquitin N terminal to methionine 1.
Fluoresceine-5-maleimide was used to modify this engineered cysteine.
Twenty micromolar UbcH7 was reacted with 150 nM Uba1, 20 mM fluores-
ceine-Ub in 25 mM HEPES, 2.5 mM MgCl2, 25 mM ATP, and 50 mM NaCl at
pH 7.0 to form the fluoresceine-UbUbcH7 thioester intermediate. This reac-
tion was quenched by the addition of apyrase followed by 5-fold dilution into
20 mM HEPES and 100 mM NaCl at pH 7.0. Pulse reaction was then added
to chase reactions containing 1 uM of the indicated HHARI mutant in 25 mM
HEPES and 50 mM NaCl at pH 7.0. Reactions were quenched at the indicated
time points in 23 SDS-PAGE running buffer, nonreducing or supplemented
with DTT as indicated.
For analytical gel filtration binding assays, all components were mixed at
10 mM in a 200 ml final reaction volume for 1 hr on ice prior to loading onto
an SD200 column (GE Healthcare) equilibrated with 25 mM Tris pH 7.6,
100mMNaCl, and 1mMDTT. Five hundred microliter fractions were collected
and run on 4%–12% gradient gels (Invitrogen) and visualized with SYPRO-
Ruby stain.
Isothermal calorimetry measurements were taken on an ITC200 (MicroCal).
HHARI, HHARIDARI, and UbcH7 were buffer-exchanged into PBS at pH 7,
1 mM DTT using NAP5 desalting columns (GE Healthcare). Proteins were
concentrated to 30 mM (HHARI, HHARIDARI) and 300 mM (UbcH7). UbcH7
was titrated against either HHARI or HHARIDARI in the sample cell at a constant
temperature of 25C. Nineteen titration measurements were made and the
data were analyzed using Origin software provided by MicroCal.
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